Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. The company has introduced three treatment options: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with type 2 diabetes (T2DM) and reduce cardiovascular outcomes in T2DM patients with cardiovascular risks.
Empagliflozin has been shown to be effective in reducing major cardiovascular events by 14% and has also been found to be effective in reducing weight and blood sugar levels in patients with T2DM. The medication has also been shown to be safe and well-tolerated in clinical trials.
Glenmark’s Glempa range is designed to cater to diverse patient needs, offering a standalone SGLT2 inhibitor, a dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor, and a combination therapy combining SGLT2 inhibition with metformin. The company aims to provide affordable, high-quality treatment options, improving health outcomes for millions of patients across India.
Commenting on the launch, Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd, said: “Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”